NBE Therapeutics (Switzerland)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 16 papers

  • Research Article
  • Citations3

Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia

  • Nov 27, 2025
  • New England Journal of Medicine
  • Hanny Al-Samkari +16
  • Open Access
  • Research Article
  • Citations2

Synthetic coevolution reveals adaptive mutational trajectories of neutralizing antibodies and SARS-CoV-2.

  • Sep 01, 2025
  • Cell systems
  • Roy A Ehling +12
  • Open Access
  • Abstract

826 Differential effect of NKG2A blockade on peripheral and intra-tumoral CD8 T cell response induced by KISIMA – VSV-GP-TAg heterologous prime-boost vaccination

  • Nov 01, 2023
  • Journal for ImmunoTherapy of Cancer
  • Erika Riva +6
  • Open Access
  • Research Article
  • Citations6

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin

  • Jul 12, 2023
  • OncoImmunology
  • Daniel Snell +22
  • Research Article

Abstract 4223: Cis-activation of PD-1+ effector T cells with dual-targeting immunocytokines generated using a novel chemical conjugation platform

  • Jun 15, 2022
  • Cancer Research
  • Jean-Philippe Carralot +5
  • Research Article
  • Citations2

Abstract 2138: Creating next-generation biologics using a novel chemistry platform technology

  • Jun 15, 2022
  • Cancer Research
  • Vijaya R Pattabiraman +6
  • Open Access
  • Preprint Article
  • Citations4

A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron

  • Jan 04, 2022
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Tom Z Yuan +13
  • Open Access
  • Conference Article

P03.02 Protein-based cancer vaccine combined with an oncolytic vaccine promotes potent antitumor immunity

  • Oct 01, 2021
  • Poster presentations
  • E Belnoue +14
  • Research Article
  • Citations7

Abstract 1204: SO-N102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels

  • Jul 01, 2021
  • Cancer Research
  • Lenka Kyrych Sadilkova +7
  • Research Article
  • Citations8

Abstract 2276: Preclinical development and mechanism of action studies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate

  • Aug 13, 2020
  • Cancer Research
  • Daniel Snell +22
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.